Hiscox Ltd (LON:HSX) Stock Rating Maintained by Peel Hunt; The GBX 910.00 Target Indicates -34.88% Potential; Shorts at Smith & Nephew Snats (SNN) Lowered By 22.95%

In a research note revealed to clients and investors on 5 March, Hiscox Ltd (LON:HSX) stock Reduce was kept by Peel Hunt. They currently have a GBX 910.00 target on the stock. Peel Hunt’s target indicates a potential downside of -34.88% from the company’s close price.

Smith & Nephew Snats Inc (NYSE:SNN) had a decrease of 22.95% in short interest. SNN’s SI was 1.22 million shares in March as released by FINRA. Its down 22.95% from 1.58M shares previously. With 470,300 avg volume, 3 days are for Smith & Nephew Snats Inc (NYSE:SNN)’s short sellers to cover SNN’s short positions. The SI to Smith & Nephew Snats Inc’s float is 0.28%. The stock increased 0.68% or $0.24 during the last trading session, reaching $35.78. About 1.39 million shares traded or 144.63% up from the average. Smith & Nephew plc (NYSE:SNN) has risen 3.46% since March 5, 2017 and is uptrending. It has underperformed by 13.24% the S&P500.

Hiscox Ltd, together with its subsidiaries, provides insurance and reinsurance services. The company has market cap of 4.02 billion GBP. The firm operates through four divisions: Hiscox Retail, Hiscox London Market, Hiscox Re and ILS, and Corporate Centre. It has a 155.56 P/E ratio. It provides commercial insurance for small-and medium-sized businesses, including household, fine art and collectibles, and luxury motor via brokers, through a growing network of partnerships, and directly to consumers.

Among 23 analysts covering Hiscox Ltd (LON:HSX), 7 have Buy rating, 4 Sell and 12 Hold. Therefore 30% are positive. Hiscox Ltd has GBX 1600 highest and GBX 645 lowest target. GBX 1152.86’s average target is -17.65% below currents GBX 1400 stock price. Hiscox Ltd had 166 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was maintained by Citigroup with “Neutral” on Monday, April 18. The stock of Hiscox Ltd (LON:HSX) earned “Overweight” rating by JP Morgan on Wednesday, August 12. The stock has “Overweight” rating by JP Morgan on Tuesday, November 8. As per Friday, September 9, the company rating was maintained by Peel Hunt. The rating was maintained by Peel Hunt on Monday, April 4 with “Reduce”. The rating was maintained by Canaccord Genuity with “Hold” on Monday, November 9. The rating was maintained by Stockdale with “Hold” on Tuesday, February 6. The stock of Hiscox Ltd (LON:HSX) earned “Underweight” rating by Barclays Capital on Tuesday, October 20. The firm has “Overweight” rating given on Friday, January 5 by JP Morgan. The firm earned “Overweight” rating on Wednesday, September 23 by JP Morgan.

The stock increased 1.45% or GBX 20 during the last trading session, reaching GBX 1400. About 59,333 shares traded. Hiscox Ltd (LON:HSX) has 0.00% since March 5, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 11 analysts covering Smith & Nephew PLC (ADR) (NYSE:SNN), 3 have Buy rating, 0 Sell and 8 Hold. Therefore 27% are positive. Smith & Nephew PLC (ADR) had 15 analyst reports since October 29, 2015 according to SRatingsIntel. The rating was downgraded by Berenberg on Thursday, October 6 to “Hold”. The rating was downgraded by Goldman Sachs to “Neutral” on Monday, February 27. The rating was upgraded by Morgan Stanley to “Overweight” on Thursday, December 8. Jefferies upgraded Smith & Nephew plc (NYSE:SNN) on Monday, May 9 to “Buy” rating. The company was initiated on Thursday, January 19 by HSBC. The stock of Smith & Nephew plc (NYSE:SNN) has “Buy” rating given on Thursday, January 25 by J.P. Morgan. As per Monday, December 11, the company rating was downgraded by Morgan Stanley. The stock of Smith & Nephew plc (NYSE:SNN) has “Equal-Weight” rating given on Wednesday, August 10 by Barclays Capital. The rating was initiated by Sterne Agee CRT on Wednesday, November 4 with “Neutral”. The stock of Smith & Nephew plc (NYSE:SNN) has “Buy” rating given on Thursday, January 4 by Canaccord Genuity.

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company has market cap of $15.37 billion. The firm offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints; and arthroscopic enabling technologies for healthcare providers, such as fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency wands, electromechanical and mechanical blades, and hand instruments for removing damaged tissue. It has a 20.4 P/E ratio. It also provides trauma and extremities products consisting of internal and external devices used in the stabilization of severe fractures and deformity correction procedures; robotics-assisted surgery services and products; knee implant products for specialized knee replacement procedures; and hip implant products for reconstruction of the hip joint, as well as various products and technologies to assist in surgical treatment of the ear, nose, and throat.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: